Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes

Diabetes

Volumn 59, Issue 6, 2010, Pages 1292-1301

  Mas, Sebastián ^a   Martínez Pinna, Roxana ^a   Martín Ventura, Jose Luis ^a   Pérez, Raul ^b   Gomez Garre, Dulcenombre ^c   Ortiz, Alberto ^a   Fernandez Cruz, Arturo ^c   Vivanco, Fernando ^d   Egido, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Nanotechnology Platform   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LINOLEIC ACID; LIPOPROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1;

AGED; ARTICLE; ATHEROMA; CAROTID ENDARTERECTOMY; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LASER MICRODISSECTION; MALE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; TIME OF FLIGHT MASS SPECTROMETRY; UPREGULATION; VASCULAR SMOOTH MUSCLE;

AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; BLOOD PRESSURE; CAROTID STENOSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDARTERECTOMY, CAROTID; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; MALE; MASS SPECTROMETRY; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; POLYMERASE CHAIN REACTION; RNA; T-LYMPHOCYTES;

EID: 77953192765     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-0848     Document Type: Article

References (46)

1. World Health Organization: Diabetes: WHO Fact Sheet No. 312 [article online], 2009. Geneva, World Health Org. Available from www.who.int/mediacentre/ factsheets/fs312/en/index.html
2. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008; 196:9-21
3. Price CL, Knight SC. Advanced glycation: a novel outlook on atherosclerosis. Curr Pharm Des 2007;13:3681-3687
4. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA. Lipid mediators of insulin resistance. Nutr Rev 2007;65:S39-S46
5. Ruddock MW, Stein A, Landaker E, Park J, Cooksey RC, McClain D, Patti ME. Saturated fatty acids inhibit hepatic insulin action by modulating insulin receptor expression and post-receptor signalling. J Biochem 2008; 144:599-607
6. Montecucco F, Steffens S, Mach F. Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm 2008:767623, 2008
7. Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 2005;25:487-496
8. Chiarelli F, Marcovecchio ML. Insulin resistance and obesity in childhood. Eur J Endocrinol 2008;159(Suppl. 1):S67-S74
9. Wilding JP. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med 2007;24:934-945
10. Armstrong KA, Hiremagalur B, Haluska BA, Campbell SB, Hawley CM, Marks L, Prins J, Johnson DW, Isbel NM. Free fatty acids are associated with obesity, insulin resistance, and atherosclerosis in renal transplant recipients. Transplantation 2005;80:937-944
11. Rodriguez-Lee M, Bondjers G, Camejo G. Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans. Curr Opin Lipidol 2007;18: 546-553
12. Brunelle A, Laprevote O. Recent advances in biological tissue imaging with time-of-flight secondary ion mass spectrometry: polyatomic ion sources, sample preparation, and applications. Curr Pharm Des 2007;13:3335-3343
13. Mas S, Touboul D, Brunelle A, Aragoncillo P, Egido J, Laprevote O, Vivanco F. Lipid cartography of atherosclerotic plaque by cluster-TOF-SIMS imaging. Analyst 2007;132:24-26
14. Touboul D, Brunelle A, Laprevote O. Structural analysis of secondary ions by post-source decay in time-of-flight secondary ion mass spectrometry. Rapid Commun Mass Spectrom 2006;20:703-709
15. Munoz-Garcia B, Martin-Ventura JL, Martinez E, Sanchez S, Hernandez G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke 2006;37:2044-2053
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408
17. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, Hernandez-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, Vivanco F, Gerique JG, Diaz C, Hernandez G, Egido J. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002;160:49-58
18. Hernandez-Presa MA, Ortego M, Tunon J, Martin-Ventura JL, Mas S, Blanco-Colio LM, Aparicio C, Ortega L, Gomez-Gerique J, Vivanco F, Egido J. Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 2003;57:168-177
19. Hernandez-Presa MA, Gomez-Guerrero C, Egido J. In situ non-radioactive detection of nuclear factors in paraffin sections by Southwestern histochemistry. Kidney Int 1999;55:209-214
20. Martin-Ventura JL, Blanco-Colio LM, Gomez-Hernandez A, Munoz-Garcia B, Vega M, Serrano J, Ortega L, Hernandez G, Tunon J, Egido J. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005;36:1796-1800
21. Erkelens DW. Diabetic dyslipidaemia. Eur Heart J 1998;19(Suppl. H):H27-H40
22. Schwertner HA, Mosser EL. Comparison of lipid fatty acids on a concentration basis vs weight percentage basis in patients with and without coronary artery disease or diabetes. Clin Chem 1993;39:659-663
23. Goldberg IJ, Merkel M. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci 2001;6:D388-D405
24. Bartels ED, Nielsen JE, Lindegaard ML, Hulten LM, Schroeder TV, Nielsen LB. Endothelial lipase is highly expressed in macrophages in advanced human atherosclerotic lesions. Atherosclerosis 2007;195:e42-e49
25. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;102: 2180-2184
26. Ping D, Boekhoudt GH, Rogers EM, Boss JM. Nuclear factor-kappa B p65 mediates the assembly and activation of the TNF-responsive element of the murine monocyte chemoattractant-1 gene. J Immunol 1999;162:727-734 (Pubitemid 29035393)
27. Qiu G, Hill JS. Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages. J Lipid Res 2007;48:2112-2122 (Pubitemid 47529554)
28. Bork PM, Schmitz ML, Kuhnt M, Escher C, Heinrich M. Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett 1997;402:85-90
29. Lopez-Franco O, Hernandez-Vargas P, Ortiz-Munoz G, Sanjuan G, Suzuki Y, Ortega L, Blanco J, Egido J, Gomez-Guerrero C. Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:1864-1870
30. Clee SM, Bissada N, Miao F, Miao L, Marais AD, Henderson HE, Steures P, McManus J, McManus B, LeBoeuf RC, Kastelein JJ, Hayden MR. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J Lipid Res 2000;41:521-531 (Pubitemid 30220655)
31. Rader DJ, Jaye M. Endothelial lipase: a new member of the triglyceride lipase gene family. Curr Opin Lipidol 2000;11:141-147 (Pubitemid 30219108)
32. Virani SS, Nambi V. The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis. Curr Atheroscler Rep 2007;9:97-103
33. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 2007;7:511-517
34. Oram JF, Bornfeldt KE. Direct effects of long-chain non-esterified fatty acids on vascular cells and their relevance to macrovascular complications of diabetes. Front Biosci 2004;9:1240-1253
35. Ichikawa T, Liang J, Kitajima S, Koike T, Wang X, Sun H, Morimoto M, Shikama H, Watanabe T, Yamada N, Fan J. Macrophage-derived lipoprotein lipase increases aortic atherosclerosis in cholesterol-fed Tg rabbits. Atherosclerosis 2005;179:87-95 (Pubitemid 40249789)
36. Haversen L, Danielsson KN, Fogelstrand L, Wiklund O. Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. Atherosclerosis 2009;202:382-393
37. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 2002;51:2005-2011 (Pubitemid 34729001)
38. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, Xiang X, Luo Z, Ruderman N. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κB pathway in rat liver. Diabetes 2005;54:3458-3465
39. Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, Mizuarai S, Kotani H, Yamaoka S, Miyake K, Aoe S, Kamei Y, Ogawa Y. Role of the toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007;27:84-91
40. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 2007;100: 1589-1596
41. Hancock CR, Han DH, Chen M, Terada S, Yasuda T, Wright DC, Holloszy JO. High-fat diets cause insulin resistance despite an increase in muscle mitochondria. Proc Natl Acad Sci U S A 2008;105:7815-7820
42. Vandewalle B, Moerman E, Lefebvre B, Defrance F, Gmyr V, Lukowiak B, Kerr Conte J, Pattou F. PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets. Biochem Biophys Res Commun 2008;366:1096-1101
43. Swaminath G. Fatty acid binding receptors and their physiological role in type 2 diabetes. Arch Pharm (Weinheim) 2008;341:753-761
44. Ragheb R, Medhat AM, Shanab GM, Seoudi DM, Fantus IG. Links between enhanced fatty acid flux, protein kinase C and NFkappaB activation, and apoB-lipoprotein production in the fructose-fed hamster model of insulin resistance. Biochem Biophys Res Commun 2008;370:134-139
45. Dey D, Basu D, Roy SS, Bandyopadhyay A, Bhattacharya S. Involvement of novel PKC isoforms in FFA induced defects in insulin signaling. Mol Cell Endocrinol 2006;246:60-64
46. Wunderlich FT, Luedde T, Singer S, Schmidt-Supprian M, Baumgartl J, Schirmacher P, Pasparakis M, Bruning JC. Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proc Natl Acad Sci U S A 2008;105:1297-1302